Trevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLC

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 175.86% from the stock’s previous close.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target on shares of Trevi Therapeutics in a report on Thursday, March 21st.

Trevi Therapeutics Stock Down 0.7 %

NASDAQ:TRVI opened at $2.90 on Wednesday. The company has a fifty day simple moving average of $3.03 and a two-hundred day simple moving average of $2.07. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The company has a market cap of $204.25 million, a price-to-earnings ratio of -10.07 and a beta of 0.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, analysts expect that Trevi Therapeutics will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TRVI. SG Americas Securities LLC purchased a new stake in Trevi Therapeutics in the third quarter valued at $43,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at about $208,000. Silverarc Capital Management LLC grew its stake in Trevi Therapeutics by 4.7% during the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after buying an additional 41,491 shares during the last quarter. Opaleye Management Inc. increased its position in Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after buying an additional 829,100 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its stake in Trevi Therapeutics by 7.3% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.